Abstract
The role of intraperitoneal chemotherapy has been widely investigated in locally advanced malignancies which serosal involvement as well as in cases in which disseminated peritoneal nodules are present. However, its benefits have been widely contested by the higher rates of perioperative complications and therefore, the guidelines did not include it as part of standard therapy. Meanwhile, the better control of the intraperitoneal spread which has been demonstrated in certain cases enabled surgeons to propose performing intraperitoneal chemotherapy in particularly aggressive malignancies such as pancreatic cancer. The aim of the current paper is to discuss about the efficacy and the preliminary results of intraperitoneal chemotherapy in pancreatic cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
